Skip to main content

Advertisement

SpringerLink
Log in

Modern treatment in Parkinson’s disease, a personal approach

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

There are many guidelines available concerning the treatment of Parkinson’s disease. Most of these advocate treating young-onset patients with a dopamine agonist and older patients with levodopa. The rationale behind this recommendation has its origins in the side effects associated with each of these drug classes: whilst levodopa leads to dyskinesia, which may not be relevant for patients with a limited life-expectancy, dopamine agonists have a much longer plasma half life which probably leads to more continuous dopamine receptor stimulation and thus decreases the occurrence and severity of dyskinesia. However, the side effects associated with the use of dopamine agonists, such as sleepiness, orthostatic problems, hallucinations and impulse control disorders are a drawback. In this overview, the hypothesis will be put forward that perhaps such a strict distinction is no longer needed. A new idea may be the early combination of levodopa with a dopamine agonist which would provide good clinical efficacy and, because of the relatively low doses involved, would reduce the side effects associated with both substances. MAO-B inhibitors may be a good option for early treatment and especially for patients who experience first motor fluctuations. Similarly, and particularly if a wearing-off symptom is present, COMT inhibitors smoothen and prolong the action of levodopa. More invasive escalation therapy comes into play when patients reach the advanced stages with problems of insufficient motor control, such as bradykinesia, rigidity and resting tremor, combined with on-time dyskinesia. The use of all oral and invasive treatment has to be individualized to gain a good motor and non-motor control and especially a good quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Abbott RD, Petrovitch J, Withe LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57:456–462

    Article  PubMed  CAS  Google Scholar 

  • Bonuccelli U, Ceravolo R, Salvetti S, D’Avino C, Del Dotto P, Rossi G, Murri L (1997) Clozapine in Parkinson’s disease tremor. Effects of acute and chronic administration. Neurology 49:1587–1590

    Article  PubMed  CAS  Google Scholar 

  • Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 016 Investigators (2014a) Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 29:229–237

    Article  PubMed  CAS  Google Scholar 

  • Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-keil D, Rueb U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 249 Suppl 3:III/1–III/5

  • Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG (2006) Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67(7 Suppl 2):S18–S23

    Article  PubMed  CAS  Google Scholar 

  • Cerosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, Micheli FE, Benarroch EE (2013) Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol 260:1332–1338

    Article  Google Scholar 

  • Chaudhuri KR, Odin P (2010) The challenge of non-motor symptoms in Parkinson’s disease. Prog Brain Res 184:325–341

    Article  PubMed  Google Scholar 

  • Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464–474

    Article  PubMed  CAS  Google Scholar 

  • Chondrogiorgi M, Tatsioni A, Reichmann H, Konitsiotis S (2014) Dopamine agonist monotherapy in Parkinson’s disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol 21:433–440

    Article  PubMed  CAS  Google Scholar 

  • Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog H, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Mehdorn HM, Koringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J, German Parkinson Study Group, Neurostimulation Section (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355:896–908

    Article  PubMed  CAS  Google Scholar 

  • Eggert KM, Oertel WH, Reichmann H (2012) Leitlinie Parkinson-Syndrome: Diagnostik und Therapie. In: Diener HC, Weimar C and Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (eds). Thieme Verlag, 5th edition

  • Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508

    Article  PubMed  CAS  Google Scholar 

  • Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908–1910

    Article  PubMed  CAS  Google Scholar 

  • Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A et al (2007) A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 78:465–469

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, Johnston AN, Mellick GD, Herting B, Reichmann H, Hummel T (2009) Prevalence of smell loss in Parkinson’s disease-a multicenter study. Parkinson Rel Disord 15:490–494

    Article  CAS  Google Scholar 

  • Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, TEMPO open-label study group (2009) Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov Disord 24:564–573

    Article  PubMed  Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442

    Article  PubMed  CAS  Google Scholar 

  • Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamäki M, Ellmén J (2012) The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations. Eur J Clin Pharmacol 68:281–289

    Article  PubMed  CAS  Google Scholar 

  • Iranzo A, Santamaria J, Rye DB, Vallderiola F, Martí MJ, Munoz E, Vilaseca I, Tolosa E (2005) Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 65:247–252

    Article  PubMed  CAS  Google Scholar 

  • Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology 41:202–205

    Article  PubMed  CAS  Google Scholar 

  • Leentjens AF, van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18:4144–4418

    Article  Google Scholar 

  • Martinez-Martin P, Rodriguez-Blaszquez C, Kurtis MM, Chaudhuri KR, NMSS Validation Group (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 15:399–406

    Google Scholar 

  • Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting: study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629

    Article  PubMed  Google Scholar 

  • Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanaquanas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, LCIG Horizon Study group (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomized, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, ADAGIO study investigators (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361:1268–1278

    Article  PubMed  CAS  Google Scholar 

  • Olanow XC, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, the STRIDE PD investigators (2013) Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28:1064–1071

    Article  CAS  Google Scholar 

  • Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183

    Article  Google Scholar 

  • Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284:1931–1938

    Article  Google Scholar 

  • Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59:1937–1943

    Article  Google Scholar 

  • Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 60:1721–1728

    Article  Google Scholar 

  • Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241–248

    Article  Google Scholar 

  • PD Med Collaborative Group (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomized trial. Lancet 384:1196–1205

    Article  Google Scholar 

  • Pogarell O, Gasser T, van Hilten JJ, Spieker S, PollentierS Meier D, Oertel WH (2002) Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomized, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72:713–720

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484–1491

    Article  PubMed  CAS  Google Scholar 

  • Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO study group (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): a randomized, double-blind, parallel-group trial. Lancet 365:947–954

    Article  PubMed  CAS  Google Scholar 

  • Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW (2011) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and posthoc analyses of the need for additional therapies, changes in UPDRS scoresk and non-motor outcomes. Lancet Neurol 10:415–423

    Article  PubMed  CAS  Google Scholar 

  • Reichmann H (2010) Clinical criteria for the diagnosis of Parkinson’s disease. Neurodeg Disord 7:284–290

    Article  Google Scholar 

  • Rizos A (2013) DICE-ET:DA impulse control European evaluation and tolerability study with immediate and extended release dopamine agonists in real life Parkinson’s disease. Poster presentation MDS congress in Sydney

  • Schapira AH (2007) Treatment options in the modern management of Parkinson’s disease. Arch Neurol 64:1083–1088

    Article  PubMed  Google Scholar 

  • Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K (2013) Pramipexole in patients with early Parkinson’s disease (PROUD): a randomized delayed-start trial. Lancet Neurol 12:747–755

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69:308–312

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seignueret E, Kistner A, Chaynes P, Ory-Magne F, Bfefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltete D, Damier P, Raoul S, Sixel-döring F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Lertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelmann H, Agid Y, Schade-Brittinger C, Deuschl G, EARLYSTIM Study Group (2013) Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 368:610–622

    Article  PubMed  CAS  Google Scholar 

  • Sharma JC, Ross IN, Rascol O, Brooks D (2008) relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 15:493–496

    Article  PubMed  CAS  Google Scholar 

  • Sharma JC, Bachmann CG, Linazasano G (2010) Classifying risk factors for dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord 16:490–497

    Article  PubMed  CAS  Google Scholar 

  • Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penne JB, Tanner C, Kieburtz K, Rudolph A, Parkinson Study Group (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51:604–612

    Article  PubMed  CAS  Google Scholar 

  • Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19:1196–1202

    Article  PubMed  Google Scholar 

  • Stiasny-Kolster K, Doerr Y, Möller JC, Höffken H, Behr TM, Oertel WH, Mayer G (2005) Combination of idiopathic REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126–137

    Article  PubMed  CAS  Google Scholar 

  • Stocchi F, Vacca IL, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62:905–910

    Article  PubMed  Google Scholar 

  • Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow WC (2010) initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease. The STRIDE PD study. Ann Neurol 68:18–27

    Article  PubMed  CAS  Google Scholar 

  • Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH, Chaudhuri KR, Koch R, Reichmann H, Ebersbach G (2013a) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80:800–809

    Article  PubMed  Google Scholar 

  • Storch A, Wolz M, Beuthien-Baumann B, Löhle M, Herting B, Schwanebeck U, Oehme L, van den Hoff J, Perick M, Grhlert X, Kotzerke J, Reichmann H (2013b) Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology 80:1754–1761

    Article  PubMed  CAS  Google Scholar 

  • Syed N, Murphy J, Zimmermann T Jr, Mark MH, Sage JI (1998) Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson’s disease. Mov Disord 13:336–338

    Article  PubMed  CAS  Google Scholar 

  • Verhagen Metman L, DelDotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50:1323–1326

    Article  PubMed  CAS  Google Scholar 

  • Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H, Dolan RJ, Hallett M (2011) Dopamine agonists and risk: impulse control disorders in Parkinson’s disease. Brain 134:1436–1446

    Article  Google Scholar 

  • Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Earl Adams BNL, 228 Study investigators (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 25:858–866

    Article  PubMed  Google Scholar 

  • Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk H, Huang GD, CSP 468 Study Group (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301:63–73

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Weinreb O, Amit T, Bar-Am O, Youdim MB (2010) Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 92:330–344

    Article  PubMed  CAS  Google Scholar 

  • Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2014) Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. doi:10.1002/mds.26016 (Epub ahead of print)

  • Wolters ECh, Braak H (2006) Parkinson’s disease: premotor clinic-pathological correlations. J Neural Transm Suppl 70:309–319

    Article  PubMed  Google Scholar 

  • Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 018 Investigators (2014b) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 29:1273–1280

    Article  PubMed  CAS  Google Scholar 

  • Ziemssen T, Reichmann H (2010) Treatment of dysautonomia in extrapyramidal disorders. Ther Adv Neurol Disord 3:53–67

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Technische Universitaet Dresden, Fetscherstrasse 74, 01307, Dresden, Germany

    Heinz Reichmann

Authors
  1. Heinz Reichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heinz Reichmann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reichmann, H. Modern treatment in Parkinson’s disease, a personal approach. J Neural Transm 123, 73–80 (2016). https://doi.org/10.1007/s00702-015-1441-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-015-1441-1

Keywords

Search

Navigation